Caprion Pharmaceuticals announced this week the appointment of Marc Riviere to the position of Executive vice president of clinical development as of January 2005.

Dr. Riveire will have overall responsibility for clinical strategy, planning and execution, the company said. His initial mandate will be to lead the clinical development efforts of Caprion’s lead clinical program, an antibody therapy for the prevention of hemolytic uremic syndrome resulting from E. coli infection.